XML 60 R45.htm IDEA: XBRL DOCUMENT v3.19.1
Revenue Recognition - Narrative (Details) - USD ($)
3 Months Ended 12 Months Ended
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Disaggregation of Revenue [Line Items]                      
Total revenues $ 2,502,624 $ 2,000,868 $ 24,448,761 $ 1,529,644 $ 8,787,234 $ 2,644,543 $ 20,412,124 $ 10,376,185 $ 30,481,897 $ 42,220,086 $ 35,368,361
Revenue recognized from deferred revenue beginning balance                 1,300,000 14,800,000  
ApolloBio                      
Disaggregation of Revenue [Line Items]                      
Total revenues                 23,000,000    
AstraZeneca                      
Disaggregation of Revenue [Line Items]                      
Total revenues                 6,900,000    
Other Counterparty                      
Disaggregation of Revenue [Line Items]                      
Total revenues                 117,000    
GeneOne (affiliated entity)                      
Disaggregation of Revenue [Line Items]                      
Revenue from Related Parties                 $ 342,000 $ 551,000 $ 1,200,000